(PHG) Koninklijke Philips - Ratings and Ratios
Medical Imaging, Patient Monitoring, Home Healthcare, Personal Care
Dividends
| Dividend Yield | 3.41% |
| Yield on Cost 5y | 2.13% |
| Yield CAGR 5y | -0.57% |
| Payout Consistency | 75.5% |
| Payout Ratio | 67.3% |
| Risk via 10d forecast | |
|---|---|
| Volatility | 31.8% |
| Value at Risk 5%th | 43.9% |
| Relative Tail Risk | -16.10% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | 0.28 |
| Alpha | -3.68 |
| CAGR/Max DD | 0.80 |
| Character TTM | |
|---|---|
| Hurst Exponent | 0.313 |
| Beta | 0.858 |
| Beta Downside | 0.867 |
| Drawdowns 3y | |
|---|---|
| Max DD | 33.81% |
| Mean DD | 11.28% |
| Median DD | 10.80% |
Description: PHG Koninklijke Philips October 14, 2025
Koninklijke Philips N.V. (PHG) is a Dutch-based health-technology group that serves North America, Greater China, and the rest of the world through three operating segments: Diagnosis & Treatment, Connected Care, and Personal Health.
In Diagnosis & Treatment, Philips supplies a full suite of imaging equipment-including MRI, X-ray, and detector-based spectral CT systems-as well as ultrasound platforms for cardiac, obstetric, and point-of-care use, plus integrated interventional X-ray suites and software that support minimally invasive coronary, peripheral vascular, and rhythm-management procedures.
The Connected Care segment delivers acute patient-management tools, emergency-care platforms, home-care monitoring, sleep-and-respiratory solutions, and vendor-agnostic software that enable clinicians to coordinate care across hospitals, clinics, and patients’ homes.
Personal Health focuses on consumer-facing products such as electric toothbrushes, infant-feeding devices, baby monitors, digital women’s-health apps, and grooming/beauty solutions, leveraging Philips’ brand equity in everyday health.
According to Philips’ FY2023 results, the company generated €20.4 billion in revenue, with an adjusted operating margin of roughly 13 %. The Connected Care segment grew 12 % YoY, driven by expanding tele-health adoption and higher demand for remote-monitoring devices, while Diagnosis & Treatment remained the largest revenue contributor but showed modest double-digit growth in its software-as-a-service offerings.
Key macro drivers for Philips include the global aging population (projected to reach 1.5 billion people over 65 by 2030), rising US Medicare and private-payer reimbursement rates for advanced imaging and remote-monitoring services, and the ongoing shift toward capital-efficient, subscription-based health-tech models that favor software-enabled hardware.
For a deeper quantitative assessment of Philips’ valuation and risk profile, you may find it useful to explore the company’s metrics on ValueRay.
Piotroski VR‑10 (Strict, 0-10) 4.0
| Net Income (165.0m TTM) > 0 and > 6% of Revenue (6% = 1.07b TTM) |
| FCFTA 0.01 (>2.0%) and ΔFCFTA -7.37pp (YES ≥ +1.0pp, WARN ≥ +0.5pp) |
| NWC/Revenue 12.64% (prev -35.92%; Δ 48.56pp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp) |
| CFO/TA 0.04 (>3.0%) and CFO 1.11b > Net Income 165.0m (YES >=105%, WARN >=100%) |
| Net Debt (6.47b) to EBITDA (2.33b) ratio: 2.78 <= 3.0 (WARN <= 3.5) |
| Current Ratio 1.32 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active) |
| Outstanding Shares last Quarter (963.8m) change vs 12m ago 5.56% (target <= -2.0% for YES) |
| Gross Margin 43.49% (prev 42.18%; Δ 1.31pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0) |
| Asset Turnover 92.95% (prev 151.3%; Δ -58.39pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0) |
| Interest Coverage Ratio 4.11 (EBITDA TTM 2.33b / Interest Expense TTM 276.0m) >= 6 (WARN >= 3) |
Altman Z'' 2.27
| (A) 0.09 = (Total Current Assets 9.28b - Total Current Liabilities 7.03b) / Total Assets 26.34b |
| (B) 0.12 = Retained Earnings (Balance) 3.21b / Total Assets 26.34b |
| (C) 0.06 = EBIT TTM 1.13b / Avg Total Assets 19.13b |
| (D) 0.87 = Book Value of Equity 13.76b / Total Liabilities 15.76b |
| Total Rating: 2.27 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D) |
ValueRay F-Score (Strict, 0-100) 48.25
| 1. Piotroski 4.0pt |
| 2. FCF Yield 1.11% |
| 3. FCF Margin 1.79% |
| 4. Debt/Equity 0.79 |
| 5. Debt/Ebitda 2.78 |
| 6. ROIC - WACC (= -2.68)% |
| 7. RoE 1.48% |
| 8. Rev. Trend -6.40% |
| 9. EPS Trend 24.14% |
What is the price of PHG shares?
Over the past week, the price has changed by +3.47%, over one month by +4.08%, over three months by +4.66% and over the past year by +9.67%.
Is PHG a buy, sell or hold?
- Strong Buy: 1
- Buy: 1
- Hold: 1
- Sell: 0
- Strong Sell: 0
What are the forecasts/targets for the PHG price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 33.8 | 19.5% |
| Analysts Target Price | 33.8 | 19.5% |
| ValueRay Target Price | 27.7 | -2.2% |
PHG Fundamental Data Overview November 21, 2025
P/E Trailing = 150.3333
P/E Forward = 14.5138
P/S = 1.4473
P/B = 2.1332
P/EG = 0.3632
Beta = 0.907
Revenue TTM = 17.78b EUR
EBIT TTM = 1.13b EUR
EBITDA TTM = 2.33b EUR
Long Term Debt = 7.24b EUR (from longTermDebt, last quarter)
Short Term Debt = 1.15b EUR (from shortTermDebt, last quarter)
Debt = 8.38b EUR (from shortLongTermDebtTotal, last quarter)
Net Debt = 6.47b EUR (from netDebt column, last quarter)
Enterprise Value = 28.63b EUR (22.16b + Debt 8.38b - CCE 1.91b)
Interest Coverage Ratio = 4.11 (Ebit TTM 1.13b / Interest Expense TTM 276.0m)
FCF Yield = 1.11% (FCF TTM 318.2m / Enterprise Value 28.63b)
FCF Margin = 1.79% (FCF TTM 318.2m / Revenue TTM 17.78b)
Net Margin = 0.93% (Net Income TTM 165.0m / Revenue TTM 17.78b)
Gross Margin = 43.49% ((Revenue TTM 17.78b - Cost of Revenue TTM 10.05b) / Revenue TTM)
Gross Margin QoQ = 44.40% (prev 46.36%)
Tobins Q-Ratio = 1.09 (Enterprise Value 28.63b / Total Assets 26.34b)
Interest Expense / Debt = 0.68% (Interest Expense 57.0m / Debt 8.38b)
Taxrate = 31.64% (87.0m / 275.0m)
NOPAT = 774.6m (EBIT 1.13b * (1 - 31.64%))
Current Ratio = 1.32 (Total Current Assets 9.28b / Total Current Liabilities 7.03b)
Debt / Equity = 0.79 (Debt 8.38b / totalStockholderEquity, last quarter 10.55b)
Debt / EBITDA = 2.78 (Net Debt 6.47b / EBITDA 2.33b)
Debt / FCF = 20.34 (Net Debt 6.47b / FCF TTM 318.2m)
Total Stockholder Equity = 11.16b (last 4 quarters mean from totalStockholderEquity)
RoA = 0.63% (Net Income 165.0m / Total Assets 26.34b)
RoE = 1.48% (Net Income TTM 165.0m / Total Stockholder Equity 11.16b)
RoCE = 6.16% (EBIT 1.13b / Capital Employed (Equity 11.16b + L.T.Debt 7.24b))
RoIC = 4.11% (NOPAT 774.6m / Invested Capital 18.86b)
WACC = 6.79% (E(22.16b)/V(30.54b) * Re(9.18%) + D(8.38b)/V(30.54b) * Rd(0.68%) * (1-Tc(0.32)))
Discount Rate = 9.18% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: 33.33 | Cagr: 1.52%
[DCF Debug] Terminal Value 65.49% ; FCFE base≈599.7m ; Y1≈393.7m ; Y5≈180.1m
Fair Price DCF = 3.11 (DCF Value 2.95b / Shares Outstanding 951.0m; 5y FCF grow -40.0% → 3.0% )
EPS Correlation: 24.14 | EPS CAGR: -14.58% | SUE: -0.11 | # QB: 0
Revenue Correlation: -6.40 | Revenue CAGR: -3.64% | SUE: -0.00 | # QB: 0
EPS next Year (2026-12-31): EPS=1.82 | Chg30d=-0.004 | Revisions Net=+0 | Growth EPS=+26.5% | Growth Revenue=+3.0%
Additional Sources for PHG Stock
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle